MDS Nordion
This article was originally published in The Gray Sheet
Executive Summary
Radioisotope technology firm plans to roll out by late spring its TheraSphere non-surgical outpatient therapy for the approximately 4,000 annual U.S. cases of inoperable hepatocellular carcinoma following the firm's Dec. 10 receipt of a humanitarian device exemption approval. TheraSphere, which consists of 20-30 um glass beads containing yttrium-90, lodges in tumor vasculature, reducing exposure of healthy tissue to radiation. The product offers advantages over traditional therapies like transarterial chemoembolization, including shorter hospital stays and fewer side effects, the firm claims
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.